<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941210</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12358</org_study_id>
    <nct_id>NCT03941210</nct_id>
  </id_info>
  <brief_title>Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients</brief_title>
  <acronym>miRNA</acronym>
  <official_title>Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of miRNAs in HIV disease is yet to be completely defined. Host miRNAs target certain&#xD;
      HIV genes, thus can affect HIV replication and participate in viral control. miRNAs can also&#xD;
      block HIV production through disruption of Gag assembly on cell membranes. miRNA expression&#xD;
      can characterize HIV disease phenotype, as has been shown in HIV elite controllers who have a&#xD;
      well-defined miRNA expression profile. However, the studies of miRNA in acute infection and&#xD;
      co-infections like tuberculosis are lacking. The investigators showed that during immune&#xD;
      reconstitution syndrome (IRIS) in HIV/TB coinfected patients, innate immune response play a&#xD;
      role as through NK cell degranulation, therefore testing for this could be used as a&#xD;
      predictive marker of IRIS.&#xD;
&#xD;
      One of the limitations of miRNA detection is the technique, which is time-consuming, and&#xD;
      needs laboratories that are specialized and equipped for molecular biology techniques. In&#xD;
      contrast, flow cytometry has been developed in routine labs and has well-standardized&#xD;
      techniques. For the routine detection of miRNA, flow cytometry could be the best way to&#xD;
      perform high throughput screening for clinical applications.&#xD;
&#xD;
      Flow cytometry is a simple and effective way to evaluate miRNAs expression. In this project&#xD;
      the investigators propose to evaluate, using flow cytometry, whether circulating miRNA&#xD;
      pattern might be applicable as potential biomarkers in prediction and prognosis of IRIS in&#xD;
      HIV/TB co-infected patients. The investigators propose to study the miRNA expression profile&#xD;
      in a cohort of patients with a HIV infection and Tuberculosis and correlate it with their&#xD;
      clinical evolution. As controls, the investigators propose to analyze expression of miRNAs in&#xD;
      healthy controls as well as TB and HIV mono-infected patients.&#xD;
&#xD;
      AIMS OF THE PROPOSAL&#xD;
&#xD;
        1. Identify miRNA expression profile as potential novel predictive and prognostic&#xD;
           biomarkers for IRIS.&#xD;
&#xD;
        2. Identify the miRNA expression profile in HIV patients, in TB patients and in HIV/TB&#xD;
           co-infected patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA expression profile in a cohort of patients with a HIV infection and Tuberculosis and correlate it with their clinical evolution</measure>
    <time_frame>March 1st 2018 - March 1st 2020</time_frame>
    <description>Evaluate, using flow cytometry, whether circulating miRNA (in plasma and/or exosomes) pattern might be applicable as potential biomarkers in prediction and prognosis of IRIS in HIV/TB co-infected patients.&#xD;
Description of miRNA expression profile in a cohort of patients with a HIV infection and Tuberculosis and correlate it with their clinical evolution.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">134</enrollment>
  <condition>HIV Infection</condition>
  <condition>Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>HIV+/TB+</arm_group_label>
    <description>Frozen samples and data from participants recruited in the ANRS 12095 CAMELIA clinical trial and the ANRS 12153 CAPRI NK study will be used for this study arm&#xD;
All plasma samples were collected before any treatment during IRIS diagnosis and at W8 post TB treatment initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+/TB-</arm_group_label>
    <description>Participants included in this study arm will be HIV+ and TB-&#xD;
One time collection of 5 ml of blood will be drawn in EDTA tube for each patient before starting cART and sent to the laboratory for protocol analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-/TB+</arm_group_label>
    <description>Participants included in this study arm will be HIV- and TB+&#xD;
Collection of 5 ml of blood drawing in EDTA tube will be requested for each patient before starting TB drug treatment and after week 2 and 8 of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-/TB-</arm_group_label>
    <description>Participants included in this study arm will be HIV- and TB-&#xD;
Clinical examination to rule out overt evidence of TB and, whenever needed, routine TB testing as per national guidelines (sputum smear ± chest X-ray) in case of symptoms/clinical manifestations suggestive of TB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Detection of molecular Biomarkers</intervention_name>
    <description>MicroRNA expression profile analysis by flow cytometry</description>
    <arm_group_label>HIV+/TB+</arm_group_label>
    <arm_group_label>HIV+/TB-</arm_group_label>
    <arm_group_label>HIV-/TB+</arm_group_label>
    <arm_group_label>HIV-/TB-</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma/cells samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. 74 TB - HIV co-infected patients (37 TB-IRIS and 37 non TB-IRIS) whose plasma were&#xD;
             stored during the ANRS 12095 CAMELIA clinical trial (NCT00226434) and ANRS 12153 CAPRI&#xD;
             NK study will be included in the study.&#xD;
&#xD;
          2. 20 HIV ART naïve patients will be enrolled in Sihanouk Hospital Center of HOPE in&#xD;
             Cambodia.&#xD;
&#xD;
          3. 20 newly active tuberculosis patients will be enrolled in Sihanouk Hospital Center of&#xD;
             HOPE in Cambodia.&#xD;
&#xD;
          4. 20 healthy individuals will be recruited from the patients coming to Pasteur Institute&#xD;
             in Cambodia for pre-marital test for HIV and who agree to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For HIV+/TB+ participants:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  cf the CAMELIA clinical trial (NCT00226434)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cf the CAMELIA clinical trial (NCT00226434)&#xD;
&#xD;
        For HIV+/TB- participants:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  HIV+&#xD;
&#xD;
          -  CD4 cell count ≤ 200 x 106 cells/l&#xD;
&#xD;
          -  No evidence of tuberculosis infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  CD4 cell count &gt; 200 x 106 cells/l&#xD;
&#xD;
          -  Evidence of tuberculosis infection&#xD;
&#xD;
          -  Non ART naive at inclusion&#xD;
&#xD;
        For HIV-/TB+ participants:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  HIV-&#xD;
&#xD;
          -  Confirmed tuberculosis infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  AFB negative or MTB/RIF negative for MTB,&#xD;
&#xD;
          -  History of TB infection&#xD;
&#xD;
          -  HIV+&#xD;
&#xD;
        For HIV-/TB- participants:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  HIV-&#xD;
&#xD;
          -  No evidence of tuberculosis infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Evidence of tuberculosis infection&#xD;
&#xD;
          -  HIV+&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Polidy PEAN, MD, PhD</last_name>
    <phone>+85512552182</phone>
    <email>polidy@pasteur-kh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Pasteur du Cambodge</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polidy PEAN, MD, PhD</last_name>
      <phone>+85512552182</phone>
      <email>polidy@pasteur-kh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microRNA</keyword>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>IRIS</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

